Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 11/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | GOT1 | P17174 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3710714 | 0.99 | BRAF (0.51) | BRAFTRPV1HTR2AHTR7HTR6 | |
| SCHEMBL3707797 | 0.92 | TRPV1 (0.49) | BRAFTRPV1P2RY1MAPTGOT1 | |
| SCHEMBL15052996 | 0.92 | BRAF (0.50) | BRAFTRPV1HTR2AHTR7HTR6 | |
| Hydrochloric Acid SCHEMBL3706731 | 0.91 | TRPV1 (0.49) | BRAFTRPV1P2RY1MAPTGOT1 | |
| SCHEMBL3705879 | 0.90 | RAB9A (0.46) | BRAFHTR2AHTR7STING1P2RY1 | |
| Hydrochloric Acid SCHEMBL3697415 | 0.90 | RAB9A (0.45) | BRAFHTR2AHTR7STING1P2RY1 | |
| SCHEMBL3705574 | 0.89 | MAPT (0.44) | BRAFHTR2AHTR7P2RY1MAPT | |
| SCHEMBL3703952 | 0.89 | NTRK1 (0.53) | TRPV1STING1P2RY1GOT1 | |
| SCHEMBL3710695 | 0.89 | RIPK1 (0.49) | BRAFHTR2AHTR7HTR6P2RY1 | |
| SCHEMBL3703390 | 0.89 | DRD2 (0.45) | BRAFSTING1MAPTGOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | claimed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | claimed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | BRAF 114/4885TRPV1 4841/4885HTR2A 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.